ArticleslgStudy

chemistry

Hubert Schoemaker

Hubert Schoemaker is a chemistry topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Hubert Schoemaker rather than just read about it. In short: Hubert Jacob Paul Schoemaker (March 23, 1950 – January 1, 2006) was a Dutch biotechnologist. He was a co-founder and the president of one of America's first biotechnology companies, Centocor, which was founded in 1979 for the commercialising of monoclonal antibodies.

Key takeaways

  • Hubert Schoemaker belongs to chemistry; place it in that map before memorising details.
  • Learn the definition first, then one example that makes the definition concrete.
  • Connect Hubert Schoemaker to a quantity you can measure, compute or draw — that is where exam questions come from.
  • Reproduce the core statement of Hubert Schoemaker from memory before moving on to harder problems.

Reference excerpt

Hubert Jacob Paul Schoemaker (March 23, 1950 – January 1, 2006) was a Dutch biotechnologist. He was a co-founder and the president of one of America's first biotechnology companies, Centocor, which was founded in 1979 for the commercialising of monoclonal antibodies. In 1999 he founded Neuronyx, Inc., for the manufacture of stem cells and the development of stem-cell therapies.

Early life and education Schoemaker was born in Deventer, Netherlands. He attended St. Bernardus School in Deventer, and Canisius College, Nijmegen. In 1969 he moved to the United States to attend the University of Notre Dame, where he majored in chemistry, graduating in May 1972. Soon after he married Ann Postorino. He then earned a doctorate in biochemistry in 1975 from the Massachusetts Institute of Technology. Supervised by Paul Schimmel, his doctoral research was an investigation of the structure function relationships of transfer RNAs and their complexes.

Career After declining postdoctoral research positions with Stanley Cohen and Klaus Weber, Schoemaker chose to work as a research scientist in industry. His choice was influenced by the severe disabilities suffered by his first daughter, Maureen, who was born with lissencephaly and needed specialised care. This inspired Schoemaker to become involved in commercial biotechnology. In 1976 Schoemaker joined Corning Medical, a Boston-based division of Corning Glass Works. At Corning Schoemaker rapidly progressed from being a specialist in immunoassay development for diagnostics to heading research and development. Among his achievements at the company was devising effective diagnostic kit tests for thyroid disorders. In 1979 Schoemaker became involved in the founding of Centocor together with a former Corning Medical colleague Ted Allen and the bioentrepreneur Michael Wall with whom he had some dealings while at Corning. Inspired by the work of Hilary Koprowski, who developed some of the earliest monoclonal antibodies against tumour antigens and influenza viral antigens, the objective of Centocor was to commercialise monoclonal antibodies for diagnostics and therapeutics. In 1980 Schoemaker joined Centocor and soon after became its first chief executive officer. From the start Centocor decided to fill its product pipeline through partnerships with research institutions and marketing alliances. Central to this policy was Schoemaker's ability to network and the company's decision to design diagnostic kits so that were compatible with existing diagnostic systems. Under Schoemaker's leadership Centocor rapidly grew into a profitable diagnostic business. By 1985 the company had revenues of approximately $50 million. In part this success was built upon the swift approval the company won for two of its tests. The first was for gastrointestinal cancer test and the other was for hepatitis B. Between 1983 and 1986 Centocor introduced three other diagnostic tests to the market: one for ovarian cancer (the first diagnostic test available for the disease), one for breast cancer and one for colorectal cancer. Despite the company's success on the diagnostic front, Schoemaker was plunged in 1992 into efforts to save the company from bankruptcy when its first therapeutic, Centoxin, a drug designed to treat septic shock, failed to win FDA approval. In part the crisis had come about as a result of the company's executives trying to go it alone in developing the drug. What saved the company was a return to the policy of collaboration. Learning from its mistakes with Centoxin, in December 1994 Centocor gained marketing approval for ReoPro, a monoclonal antibody drug for cardiovascular disease. The first therapeutic to ever receive simultaneous US and European approvals, and the second monoclonal antibody to ever win approval as a drug, ReoPro marked a milestone for both Centocor and for monoclonal antibodies therapeutics. ReoPro was to be followed in August 1998 by the approval of Centocor's Remicade, a drug to treat auto-immune disorders like Crohn's disease and rheumatoid arthritis. After selling Centocor to Johnson and Johnson in 1999, Schoemaker went on to form Neuronyx, Inc., a biotech company focused on developing cellular therapies. After Schoemaker died in 2006 the company was continued by his wife Anne Faulkner Schoemaker. Initial work focused on using stem cells taken from adult bone marrow to help regenerate heart tissue damaged during heart attacks. Later the company turned direction to looking at the development of a treatment for incision wounds in women following breast cancer reconstruction surgery. The company later changed its name to Garnet BioTherapeutics. Despite promising clinical results and raising more than $55 million in venture capital funding, the company was unable to continue.

Death Schoemaker was diagnosed in 1994 with a form of brain cancer, medulloblastoma. He died on January 1, 2006, at age 55.

References

External links Hubert Schoemaker on WhatisBiotechnology.org Center for Oral History. "Hubert J.P. Schoemaker". Science History Institute. Marks, Lara; Everson, Ted; Dionisio, Jen, eds. (9 July 1997). The Life of Hubert J. P. Schoemaker (1950–2006) An Oral History (PDF). Philadelphia, PA: Chemical Heritage Foundation.

Worked examples

Example 1 — a first encounter with Hubert Schoemaker

Start with the simplest possible case. Write down what Hubert Schoemaker claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In chemistry, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Hubert Schoemaker before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Hubert Schoemaker ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Hubert Schoemaker

In research
Hubert Schoemaker appears in chemistry research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry
Engineering practice reuses Hubert Schoemaker in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom
Hubert Schoemaker is common in secondary-school and first-year university syllabi. It links to neighbouring topics 1950 births, 2006 deaths, 20th-century American businesspeople, so understanding it makes those chapters shorter.
In everyday life
Look for Hubert Schoemaker outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.
Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Hubert Schoemaker” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Hubert Schoemaker in 20 minutes

  1. Read the reference excerpt below once, without taking notes.
  2. Close the page and write down what Hubert Schoemaker means in your own words.
  3. Compare your version with the excerpt and mark what you missed.
  4. Work through the three examples above with pen and paper.
  5. Explain Hubert Schoemaker out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Hubert Schoemaker in simple terms?

Hubert Jacob Paul Schoemaker (March 23, 1950 – January 1, 2006) was a Dutch biotechnologist. He was a co-founder and the president of one of America's first biotechnology companies, Centocor, which was founded in 1979 for the commercialising of monoclonal antibodies.

Why does Hubert Schoemaker matter?

Because it connects several chemistry ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Hubert Schoemaker?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Hubert Schoemaker.

Tags

  • 1950 births
  • 2006 deaths
  • 20th-century American businesspeople
  • American biochemists
  • American immunologists
  • Biotechnologists
  • Deaths from brain cancer in the United States
  • Dutch businesspeople
  • Dutch emigrants to the United States
  • Dutch immunologists
  • MIT School of Science alumni
  • People from Deventer

Keep exploring